N4 Pharma (0GO) Stock Statistics & Valuation Metrics
Total Valuation
N4 Pharma has a market cap or net worth of EUR 16.96M. The enterprise value is EUR 4.01M.
- Market Cap
- EUR 16.96M
- Enterprise Value
- EUR 4.01M
Share Statistics
N4 Pharma has 1,775,721,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,775,721,000
- Owned by Insiders
- 0.19%
- Owned by Institutions
- ―
Financial Efficiency
N4 Pharma’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -103.14%.
- Return on Equity (ROE)
- -1.13
- Return on Assets (ROA)
- -1.03
- Return on Invested Capital (ROIC)
- -103.14%
- Return on Capital Employed (ROCE)
- -1.03
- Revenue Per Employee
- 2,421.333
- Profits Per Employee
- -401.70K
- Employee Count
- 3
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of N4 Pharma is -7.19. N4 Pharma’s PEG ratio is -0.07.
- PE Ratio
- -7.19
- PS Ratio
- 663.19
- PB Ratio
- 1.98
- Price to FCF
- -3.27
- Price to Operating Cash Flow
- -3.34
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, N4 Pharma had revenue of 7,264 and earned -1.21M in profits. Earnings per share was -0.00.
- Revenue
- 7,264
- Gross Profit
- 7,264
- Operating Income
- -1.10M
- Pretax Income
- -1.10M
- Net Income
- -1.21M
- EBITDA
- -1.10M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -1.46M and capital expenditures 0, giving a free cash flow of -1.46M billion.
- Operating Cash Flow
- -1.46M
- Free Cash Flow
- -1.46M
- Free Cash Flow per Share
- -0.00
Dividends & Yields
N4 Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -30.54%
- Earnings Yield
- -29.94%
Stock Price Statistics
- Beta
- -31.25
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 1,500
Important Dates
N4 Pharma upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 30, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
N4 Pharma as a current ratio of 11.93, with Debt / Equity ratio of 0.00%
- Current Ratio
- 11.93
- Quick Ratio
- 11.93
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.98
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, N4 Pharma has paid 104.12K in taxes.
- Income Tax
- 104.12K
- Effective Tax Rate
- -0.09
Enterprise Valuation
N4 Pharma EV to EBITDA ratio is -2.36, with an EV/FCF ratio of -2.25.
- EV to Sales
- 455.02
- EV to EBITDA
- -2.36
- EV to Free Cash Flow
- -2.25
- EV to Operating Cash Flow
- -2.25
Balance Sheet
N4 Pharma has EUR 1.50M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 1.50M billion.
- Cash & Marketable Securities
- EUR 1.50M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 1.50M
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is 0.00%, with operating margin of -19277.61%, and net profit margin of -20253.20%.
- Gross Margin
- 0.00%
- Operating Margin
- -19277.61%
- Pretax Margin
- -19277.61%
- Net Profit Margin
- -20253.20%
- EBITDA Margin
- -19277.61%
- EBIT Margin
- -19277.61%
Analyst Forecast
The average price target for N4 Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -1.23%
- EPS Growth Forecast
- 28.57%